These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1804864)

  • 21. Pharmacokinetics of esmolol and ASL-8123 in renal failure.
    Flaherty JF; Wong B; La Follette G; Warnock DG; Hulse JD; Gambertoglio JG
    Clin Pharmacol Ther; 1989 Mar; 45(3):321-7. PubMed ID: 2563962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy.
    Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.
    Bonati M; Traina GL; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G
    Br J Clin Pharmacol; 1988 Jun; 25(6):761-5. PubMed ID: 2974299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes.
    Satirapoj B; Supasyndh O; Phantana-Angkul P; Ruangkanchanasetr P; Nata N; Chaiprasert A; Kanjanakul I; Choovichian P
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S87-93. PubMed ID: 22043573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships.
    Szpunar GJ; Albert KS; Bole GG; Dreyfus JN; Lockwood GF; Wagner JG
    Biopharm Drug Dispos; 1987; 8(3):273-83. PubMed ID: 3593904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
    Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis.
    Lam YW; Flaherty JF; Yumena L; Schoenfeld PY; Gambertoglio JG
    J Antimicrob Chemother; 1995 Jul; 36(1):157-63. PubMed ID: 8537262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
    Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of flurbiprofen in man: influence of stereochemistry and age.
    Patel BK; Jackson SH; Swift CG; Hutt AJ
    Xenobiotica; 2003 Oct; 33(10):1043-57. PubMed ID: 14555340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis.
    Grech-Bélanger O; Langlois S; LeBoeuf E
    J Clin Pharmacol; 1988 May; 28(5):477-80. PubMed ID: 3392246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
    Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease.
    Mathialahan T; Sandle GI
    Nephrol Dial Transplant; 2003 Feb; 18(2):341-7. PubMed ID: 12543890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The disposition and metabolism of flurbiprofen in several species including man.
    Risdall PC; Adams SS; Crampton EL; Marchant B
    Xenobiotica; 1978 Nov; 8(11):691-703. PubMed ID: 103331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.
    Dias C; Moore KT; Murphy J; Ariyawansa J; Smith W; Mills RM; Weir MR
    Am J Nephrol; 2016; 43(4):229-36. PubMed ID: 27100875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
    Wang X; Tirucherai G; Marbury TC; Wang J; Chang M; Zhang D; Song Y; Pursley J; Boyd RA; Frost C
    J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis.
    Pai SM; Kambhampati SRP; Naruhashi S; Yamada H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):683-690. PubMed ID: 37203396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis.
    Mottet JJ; Horber FF; Casez JP; Descoeudres C; Jaeger P
    J Bone Miner Res; 1996 Jan; 11(1):96-104. PubMed ID: 8770702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of acetazolamide during CAPD.
    Schwenk MH; Blaustein DA; Wagner JD
    Adv Perit Dial; 1994; 10():44-6. PubMed ID: 7999862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyridinium crosslinks in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Ibrahim S; Mojiminiyi S; Barron JL
    Nephrol Dial Transplant; 1995 Dec; 10(12):2290-4. PubMed ID: 8808228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.